Symrise/€SY1

1D1W1MYTD1Y5YMAX

About Symrise

Symrise AG, trading under the ticker SY1, is a global supplier of fragrances, flavorings, cosmetic active ingredients, and raw materials, as well as functional ingredients. The company operates in two segments: Taste, Nutrition & Health, and Scent & Care. Symrise was founded in 2003 and is headquartered in Holzminden, Germany, continuing a legacy of the original Haarmann & Reimer company established in 1874.
Ticker
€SY1
Sector
Materials
Primary listing
XETRA
Employees
12,936
Headquarters
Holzminden, Germany
Website
www.symrise.com

Symrise Metrics

BasicAdvanced
€13B
52.95
€1.77
0.58
€1.25
1.34%

What the Analysts think about Symrise

Analyst ratings (Buy, Hold, Sell) for Symrise stock.
Analyst projections of the future price of Symrise stock.

Bulls say / Bears say

Organic sales growth accelerated to 4.5% in Q2 after a weak first quarter, led by Food & Beverage, Consumer Fragrance and Aroma Molecules. Management expects similar momentum in Q3 and has reaffirmed 2% to 4% organic growth for 2026. (Symrise)
Cash generation improved sharply: adjusted Business Free Cash Flow rose 47% and its margin increased by 450 basis points to 13.7%, while the adjusted EBITDA margin held at 21.8%. Continued ONE SYM efficiency gains could fund reinvestment and help support the 5% to 7% medium-term organic growth target. (Symrise, Quartr)
Symrise has completed its acquisition of Floral Concept, adding premium natural fragrance ingredients and complementary Grasse capabilities to Maison Lautier 1795. The combined platform should strengthen its position in differentiated, higher-value premium naturals. (MarketScreener, Reuters)
H1 adjusted EBITDA fell 1.9%, the margin slipped to 21.8%, and net profit also declined. Higher freight and logistics costs, raw materials and investment in the ONE SYM transformation are squeezing earnings before efficiency gains fully flow through. (Symrise, Roic AI)
The recovery is not yet broad or proven: Q1 organic sales fell 0.4%, H1 growth was only 2%, Pet Food declined slightly in Q2 and Scent & Care was flat for the half-year. The 2% to 4% full-year target therefore depends on further sequential improvement. (Symrise, MarketScreener)
Valuation leaves less room for execution misses after the shares’ strong rebound. A cautious fair-value estimate put the stock at €75 versus about €91, while Goldman Sachs was reported at Neutral with a €79 target, despite the expected earnings recovery. (Simply Wall St, Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.

Symrise Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Symrise Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Symrise

AllEURGBPUSD
Funds
Fund name
Fund size
€SY1 weighting
iShares STOXX Europe 600 Chemicals€EXV7
€104M5.79%
iShares EURO STOXX Mid€DJMC
€572M1.51%
iShares EURO STOXX Mid Cap£DJMC
£491M1.51%
iShares STOXX Europe Mid 200€EXSD
€610M0.76%
iShares Core DAX€EXS1
€8.6B0.71%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.